Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

<ns4:p><ns4:bold>Background</ns4:bold>: RTS,S/AS01 <ns4:sub>E</ns4:sub>, the most advanced malaria vaccine confers partial immunity. The vaccine-induced pre-erythrocytic immunity reduces exposure to blood-stage parasites, delaying acquisition of antibodies to blood-stage antigens.  However, the duration of this effect is unknown.</ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> We measured, by enzyme-linked immunosorbent assay, IgG-antibodies to 4 <ns4:italic>Plasmodium falciparum </ns4:italic>blood-stage antigens (AMA1, MSP1<ns4:sub>42</ns4:sub>, EBA175, and MSP3) on 314 children randomized to receive RTS,S/AS01 <ns4:sub>E</ns4:sub> or Rabies vaccine at 5 – 17 months of age in a phase 2b trial in Kenya, and thereafter participated in a 7-year study of the duration of vaccine immunity.</ns4:p><ns4:p> <ns4:bold>Results</ns4:bold>: Antibody levels to MSP1<ns4:sub>42</ns4:sub>, AMA1 and EBA175 were slightly lower among the RTS,S/AS01 <ns4:sub>E</ns4:sub> recipients, relative to the Rabies-control vaccinees, during the first 48 months of surveillance. Irrespective of vaccine arm, antibody levels to merozoite antigens were positively associated with the risk for malaria. However, this was only apparent at high levels for EBA175 and AMA1 and was not evident after adjusting for heterogeneity in malaria-exposure. Among children with asymptomatic parasitaemia, antibody levels were associated with reduced clinical malaria.</ns4:p><ns4:p> <ns4:bold>Conclusions</ns4:bold>: The reduction in levels of antibodies to blood-stage antigens induced by vaccination with RTS,S/AS01 <ns4:sub>E</ns4:sub> can last for several years. In absence of asymptomatic infection, anti-merozoite antibody levels were unreliable correlates of clinical immunity.</ns4:p>

Original publication

DOI

10.12688/wellcomeopenres.15002.1

Type

Journal article

Journal

Wellcome Open Research

Publisher

F1000 ( Faculty of 1000 Ltd)

Publication Date

05/03/2019

Volume

4

Pages

42 - 42